SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemiaConstanze Schneider, Jindřich Činátl, Hubert Serve et al.|Nature Medicine|2016Cited by 185
An overview and a roadmap for artificial intelligence in hematology and oncologyWiebke Rösler, Jakob Nikolas Kather, Michael Altenbuchinger et al.|Journal of Cancer Research and Clinical Oncology|2023Cited by 84
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan‐Niklas Eckardt, Jan Moritz Middeke, Friedrich Stölzel et al.|Journal of Hematology & Oncology|2022Cited by 58
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligenceJan‐Niklas Eckardt, Jan Moritz Middeke, Waldemar Hahn et al.|npj Digital Medicine|2024Cited by 58
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan‐Niklas Eckardt, Jan Moritz Middeke, Christoph Röllig et al.|Haematologica|2022Cited by 47